Chongqing Lummy Pharmaceutical (300006) - Net Assets
Based on the latest financial reports, Chongqing Lummy Pharmaceutical (300006) has net assets worth CN¥1.85 Billion CNY (≈ $271.01 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.76 Billion ≈ $404.21 Million USD) and total liabilities (CN¥910.32 Million ≈ $133.21 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300006 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.85 Billion |
| % of Total Assets | 67.05% |
| Annual Growth Rate | 20.63% |
| 5-Year Change | 52.92% |
| 10-Year Change | 11.45% |
| Growth Volatility | 67.64 |
Chongqing Lummy Pharmaceutical - Net Assets Trend (2006–2024)
This chart illustrates how Chongqing Lummy Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Also explore 300006 asset base for the complete picture of this company's asset base.
Annual Net Assets for Chongqing Lummy Pharmaceutical (2006–2024)
The table below shows the annual net assets of Chongqing Lummy Pharmaceutical from 2006 to 2024. For live valuation and market cap data, see Chongqing Lummy Pharmaceutical market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.88 Billion ≈ $275.59 Million |
-11.25% |
| 2023-12-31 | CN¥2.12 Billion ≈ $310.54 Million |
-2.87% |
| 2022-12-31 | CN¥2.18 Billion ≈ $319.73 Million |
-1.23% |
| 2021-12-31 | CN¥2.21 Billion ≈ $323.70 Million |
+79.61% |
| 2020-12-31 | CN¥1.23 Billion ≈ $180.22 Million |
-25.53% |
| 2019-12-31 | CN¥1.65 Billion ≈ $241.99 Million |
-4.08% |
| 2018-12-31 | CN¥1.72 Billion ≈ $252.28 Million |
+0.07% |
| 2017-12-31 | CN¥1.72 Billion ≈ $252.11 Million |
+2.90% |
| 2016-12-31 | CN¥1.67 Billion ≈ $245.00 Million |
-0.92% |
| 2015-12-31 | CN¥1.69 Billion ≈ $247.28 Million |
+66.17% |
| 2014-12-31 | CN¥1.02 Billion ≈ $148.81 Million |
-9.66% |
| 2013-12-31 | CN¥1.13 Billion ≈ $164.73 Million |
+58.44% |
| 2012-12-31 | CN¥710.51 Million ≈ $103.97 Million |
+7.62% |
| 2011-12-31 | CN¥660.17 Million ≈ $96.60 Million |
+17.55% |
| 2010-12-31 | CN¥561.59 Million ≈ $82.18 Million |
+6.95% |
| 2009-12-31 | CN¥525.08 Million ≈ $76.84 Million |
+281.08% |
| 2008-12-31 | CN¥137.79 Million ≈ $20.16 Million |
+27.69% |
| 2007-12-31 | CN¥107.91 Million ≈ $15.79 Million |
+67.59% |
| 2006-12-31 | CN¥64.39 Million ≈ $9.42 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chongqing Lummy Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1989.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥1.06 Billion | 56.31% |
| Other Components | CN¥1.37 Billion | 73.31% |
| Total Equity | CN¥1.88 Billion | 100.00% |
Chongqing Lummy Pharmaceutical Competitors by Market Cap
The table below lists competitors of Chongqing Lummy Pharmaceutical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cymbria Corporation
TO:CYB
|
$987.87 Million |
|
Kuros Biosciences AG
SW:KURN
|
$988.78 Million |
|
TWO HARBORS INV. DL-0001
F:2H2
|
$989.19 Million |
|
Pacira BioSciences, Inc.
NASDAQ:PCRX
|
$989.57 Million |
|
Queclink Wireless Solutions Co Ltd
SHE:300590
|
$987.30 Million |
|
Hana Materials Inc
KQ:166090
|
$986.95 Million |
|
Far Eastern Department Stores Ltd
TW:2903
|
$985.30 Million |
|
Guangdong LingXiao Pump Industry Co Ltd
SHE:002884
|
$985.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chongqing Lummy Pharmaceutical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,080,651,568 to 1,875,295,205, a change of -205,356,363 (-9.9%).
- Net loss of 87,804,417 reduced equity.
- Dividend payments of 10,764,404 reduced retained earnings.
- Other comprehensive income decreased equity by 10,254,977.
- Other factors decreased equity by 96,532,565.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-87.80 Million | -4.68% |
| Dividends Paid | CN¥10.76 Million | -0.57% |
| Other Comprehensive Income | CN¥-10.25 Million | -0.55% |
| Other Changes | CN¥-96.53 Million | -5.15% |
| Total Change | CN¥- | -9.87% |
Book Value vs Market Value Analysis
This analysis compares Chongqing Lummy Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 17.99x to 3.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.36 | CN¥6.39 | x |
| 2007-12-31 | CN¥0.35 | CN¥6.39 | x |
| 2008-12-31 | CN¥0.28 | CN¥6.39 | x |
| 2009-12-31 | CN¥0.99 | CN¥6.39 | x |
| 2010-12-31 | CN¥0.85 | CN¥6.39 | x |
| 2011-12-31 | CN¥0.95 | CN¥6.39 | x |
| 2012-12-31 | CN¥0.99 | CN¥6.39 | x |
| 2013-12-31 | CN¥1.61 | CN¥6.39 | x |
| 2014-12-31 | CN¥1.49 | CN¥6.39 | x |
| 2015-12-31 | CN¥2.39 | CN¥6.39 | x |
| 2016-12-31 | CN¥2.10 | CN¥6.39 | x |
| 2017-12-31 | CN¥2.07 | CN¥6.39 | x |
| 2018-12-31 | CN¥2.09 | CN¥6.39 | x |
| 2019-12-31 | CN¥1.92 | CN¥6.39 | x |
| 2020-12-31 | CN¥1.44 | CN¥6.39 | x |
| 2021-12-31 | CN¥2.17 | CN¥6.39 | x |
| 2022-12-31 | CN¥2.01 | CN¥6.39 | x |
| 2023-12-31 | CN¥1.98 | CN¥6.39 | x |
| 2024-12-31 | CN¥1.78 | CN¥6.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chongqing Lummy Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.04%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.52x
- Recent ROE (-4.68%) is below the historical average (3.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 13.30% | 8.86% | 0.77x | 1.95x | CN¥2.12 Million |
| 2007 | 22.75% | 14.75% | 0.77x | 1.99x | CN¥13.73 Million |
| 2008 | 23.87% | 12.40% | 0.99x | 1.95x | CN¥19.11 Million |
| 2009 | 7.71% | 12.13% | 0.51x | 1.24x | CN¥-12.04 Million |
| 2010 | 7.84% | 11.62% | 0.43x | 1.58x | CN¥-12.11 Million |
| 2011 | 11.71% | 13.68% | 0.49x | 1.73x | CN¥10.65 Million |
| 2012 | 8.14% | 8.51% | 0.44x | 2.16x | CN¥-12.27 Million |
| 2013 | 5.54% | 8.01% | 0.35x | 1.99x | CN¥-49.01 Million |
| 2014 | 0.93% | 1.02% | 0.41x | 2.26x | CN¥-90.13 Million |
| 2015 | 1.26% | 2.14% | 0.31x | 1.89x | CN¥-143.43 Million |
| 2016 | 0.43% | 0.71% | 0.40x | 1.53x | CN¥-155.66 Million |
| 2017 | 3.28% | 4.33% | 0.47x | 1.62x | CN¥-113.59 Million |
| 2018 | 5.77% | 6.27% | 0.50x | 1.85x | CN¥-71.95 Million |
| 2019 | -9.97% | -8.35% | 0.53x | 2.25x | CN¥-310.80 Million |
| 2020 | -27.90% | -20.64% | 0.50x | 2.69x | CN¥-443.90 Million |
| 2021 | -4.66% | -8.20% | 0.42x | 1.36x | CN¥-316.16 Million |
| 2022 | -3.23% | -7.77% | 0.29x | 1.44x | CN¥-281.15 Million |
| 2023 | -0.43% | -1.00% | 0.31x | 1.39x | CN¥-216.99 Million |
| 2024 | -4.68% | -11.04% | 0.28x | 1.52x | CN¥-275.33 Million |
Industry Comparison
This section compares Chongqing Lummy Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $1,573,755,484
- Average return on equity (ROE) among peers: 5.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chongqing Lummy Pharmaceutical (300006) | CN¥1.85 Billion | 13.30% | 0.49x | $987.34 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $215.92 Million | 3.15% | 4.29x | $809.52 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $439.28 Million | 4.77% | 0.63x | $403.85 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $994.04 Million | 25.25% | 0.93x | $916.62 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $481.54 Million | 6.36% | 0.40x | $374.97 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $703.64 Million | -28.08% | 0.71x | $1.99 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $684.48 Million | 0.22% | 0.18x | $433.71 Million |
| Sichuan Kelun Pharmaceutical Co Ltd (002422) | $9.06 Billion | 12.00% | 0.65x | $8.08 Billion |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $1.49 Billion | 3.03% | 0.44x | $1.56 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $90.44 Million | 20.35% | 0.22x | $1.95 Billion |
About Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more